Literature DB >> 31385729

Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis.

Fahimeh Ramezani Tehrani1, Mina Amiri1, Samira Behboudi-Gandevani1, Razieh Bidhendi-Yarandi1,2, Enrico Carmina3.   

Abstract

This study aimed to evaluate the prevalence (P)/hazard ratio (HR) of cardiovascular (CV) events among reproductive age and menopausal age women with polycystic ovary syndrome (PCOS) in comparison with healthy controls. PubMed, Scopus, ScienceDirect, Web of science, and Google scholar were searched for retrieving observational studies published up to April 2018 investigating CV events in patients with PCOS. The primary outcomes were a composite outcome of CV events [including coronary arterial disease (CAD), cardiovascular disease (CVD), myocardial infarction (MI), angina, heart failure, and ischemic heart disease] and mortality due to CV events; secondary outcomes were specific CVD events, including cerebrovascular disease, CAD, CVD, MI, angina, heart failure, ischemic heart disease, and stroke. In this meta-analysis, both fixed and random effect models were used. Potential sources of heterogeneity were explored by meta-regression and subgroup analyses. Sixteen studies including 12 population-based were analyzed for the meta-analysis. Results showed that the pooled HRs of CV events in PCOS patients of reproductive age and in menopausal/aging women were higher than healthy controls (pooled HR: 1.38, 95% CI: 1.12-1.71) and (pooled HR: 1.53, 95% CI: 1.15, 2.04), respectively. Compared to healthy controls, analysis of population-based studies revealed that the HR of CV events increased only in reproductive age PCOS patients (1.43-fold, 95% CI: 1.27, 1.61), whereas the difference was not statistically significant when comparing menopausal/aging PCOS patients to healthy controls (1.03-fold, 95% CI: 0.41, 2.59). Sufficient data were not available for comparing the HRs of mortality due to CV events between the two PCOS age groups. Mainly based on population-based study, we found a greater risk of CV events in reproductive aged but not in menopausal/aging PCOS women, suggesting that having a history of PCOS during reproductive ages may not be an important risk factor for developing events in later life. This is a preliminary assumption and needs to be reevaluated by further comprehensive cohort studies of longer duration, initiated in the reproductive period, considering all known CVD risk factors.

Entities:  

Keywords:  Cardiovascular disease; hazard ratio; meta-analysis; polycystic ovary syndrome (PCOS)

Year:  2019        PMID: 31385729     DOI: 10.1080/09513590.2019.1650337

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  13 in total

1.  Effect of GLP-1 Receptor Agonists in the Cardiometabolic Complications in a Rat Model of Postmenopausal PCOS.

Authors:  Edgar D Torres Fernandez; Alexandra M Huffman; Maryam Syed; Damian G Romero; Licy L Yanes Cardozo
Journal:  Endocrinology       Date:  2019-12-01       Impact factor: 4.736

2.  Clinical practice guideline of the Interamerican Society of Cardiology on primary prevention of cardiovascular disease in women.

Authors:  Mildren A Del-Sueldo; María A Mendonça-Rivera; Martha B Sánchez-Zambrano; Judith Zilberman; Ana G Múnera-Echeverri; María Paniagua; Lourdes Campos-Alcántara; Claudia Almonte; Amalia Paix-Gonzales; Claudia V Anchique-Santos; Claudine J Coronel; Gabriela Castillo; María G Parra-Machuca; Ivanna Duro; Paola Varletta; Patricia Delgado; Verónica I Volberg; Adriana C Puente-Barragán; Adriana Rodríguez; Aida Rotta-Rotta; Anabela Fernández; Ana C Izeta-Gutiérrez; Ana E Ancona-Vadillo; Analía Aquieri; Andrea Corrales; Andrea Simeone; Bibiana Rubilar; Carolina Artucio; Carolina Pimentel-Fernández; Celi Marques-Santos; Clara Saldarriaga; Christian Chávez; Cristina Cáceres; Dahiana Ibarrola; Daniela Barranco; Edison Muñoz-Ortiz; Edith D Ruiz-Gastelum; Eduardo Bianco; Elena Murguía; Enrique Soto; Fabiola Rodríguez-Caballero; Fanny Otiniano-Costa; Giovanna Valentino; Iris B Rodríguez-Cermeño; Ivan R Rivera; Jairo A Gándara-Ricardo; Jesús A Velásquez-Penagos; Judith Torales; Karina Scavenius; Karen Dueñas-Criado; Laura García; Laura Roballo; Lucía R Kazelian; Macarena Coussirat-Liendo; María C Costa-Almeida; Mariana Drever; Mariela Lujambio; Marildes L Castro; Maritza Rodríguez-Sifuentes; Mónica Acevedo; Mónica Giambruno; Mónica Ramírez; Nancy Gómez; Narcisa Gutiérrez-Castillo; Onelia Greatty; Paola Harwicz; Patricia Notaro; Rocío Falcón; Rosario López; Sady Montefilpo; Sara Ramírez-Flores; Silvina Verdugo; Soledad Murguía; Sonia Constantini; Thais C Vieira; Virginia Michelis; César M Serra
Journal:  Arch Cardiol Mex       Date:  2022

3.  Pregnancy Protects Hyperandrogenemic Female Rats From Postmenopausal Hypertension.

Authors:  Noha M Shawky; Chetan N Patil; Carolina Dalmasso; Rodrigo O Maranon; Damian G Romero; Heather Drummond; Jane F Reckelhoff
Journal:  Hypertension       Date:  2020-08-03       Impact factor: 10.190

4.  Age-specific cut-off levels of anti-Müllerian hormone can be used as diagnostic markers for polycystic ovary syndrome.

Authors:  Fahimeh Ramezani Tehrani; Maryam Rahmati; Fatemeh Mahboobifard; Faezeh Firouzi; Nazanin Hashemi; Fereidoun Azizi
Journal:  Reprod Biol Endocrinol       Date:  2021-05-22       Impact factor: 5.211

5.  Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists.

Authors:  Angela H E M Maas; Giuseppe Rosano; Renata Cifkova; Alaide Chieffo; Dorenda van Dijken; Haitham Hamoda; Vijay Kunadian; Ellen Laan; Irene Lambrinoudaki; Kate Maclaran; Nick Panay; John C Stevenson; Mick van Trotsenburg; Peter Collins
Journal:  Eur Heart J       Date:  2021-03-07       Impact factor: 29.983

6.  Effect of lifestyle modifications on anthropometric, clinical, and biochemical parameters in adolescent girls with polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Somayeh Abdolahian; Fahimeh Ramezani Tehrani; Mina Amiri; Delaram Ghodsi; Razieh Bidhendi Yarandi; Mahdi Jafari; Hamid Alavi Majd; Fatemeh Nahidi
Journal:  BMC Endocr Disord       Date:  2020-05-19       Impact factor: 2.763

7.  Causal relationship between polycystic ovary syndrome and coronary artery disease: A Mendelian randomisation study.

Authors:  Pomme I H G Simons; Merel E B Cornelissen; Olivier Valkenburg; N Charlotte Onland-Moret; Yvonne T van der Schouw; Coen D A Stehouwer; Stephen Burgess; Martijn C G J Brouwers
Journal:  Clin Endocrinol (Oxf)       Date:  2021-09-15       Impact factor: 3.523

8.  Clinical Practice Guidelines on Menopause: *An Executive Summary and Recommendations: Indian Menopause Society 2019-2020.

Authors:  Meeta Meeta; Leela Digumarti; Neelam Agarwal; Nirmala Vaze; Rashmi Shah; Sonia Malik
Journal:  J Midlife Health       Date:  2020-08-10

9.  Persistent organic pollutants and couple fecundability: a systematic review.

Authors:  Linda G Kahn; Kim G Harley; Eva L Siegel; Yeyi Zhu; Pam Factor-Litvak; Christina A Porucznik; Michele Klein-Fedyshin; Alison E Hipwell
Journal:  Hum Reprod Update       Date:  2021-02-19       Impact factor: 15.610

10.  Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression.

Authors:  Mina Amiri; Fahimeh Ramezani Tehrani; Samira Behboudi-Gandevani; Razieh Bidhendi-Yarandi; Enrico Carmina
Journal:  Reprod Biol Endocrinol       Date:  2020-03-17       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.